Co-delivery of Tacrolimus and Thymoquinone topically by Nanostructured lipid carriers gel for enhanced efficacy against imiquimod-induced psoriasis in Balb/c mice
Abstract
The
primary
objective
of
this
current
investigation
is
to
evaluate
the
antipsoriatic
potential
a
novel
nanogel
delivery
system
that
co-encapsulates
tacrolimus
and
thymoquinone
within
nanostructured
lipid
carriers
(NLCs).
Therefore,
TAC-THQ-NLCs-gel
was
formulated
by
emulsification
solvent-evaporation
technique
evaluated
for
their
in
improving
skin
permeation,
bioavailability,
safety,
therapeutic
efficacy
imiquimod-induced
psoriasis
mice
plaque
model.
ex-vivo
permeation
study
shows
2.51-
2.12-folds
higher
as
compared
TAC-THQ-suspension-gel,
also
enhancement
mechanism
NLCs
gel
confirmed
using
FTIR
DSC.
Further
retention
2.87-
2.36-fold
improvement
drug
free
formulation.
Further,
dermatokinetic
2.78
2.37
folds
Cmax
2.93-
2.40-fold
AUC
(area
under
curve)
TAC
THQ
respectively
drugs
gel.
results
in-vivo
compliance
suggested
fabricated
safe
delivery.
Furthermore,
TAC-THQ-NLCS-gel
represented
much
better
amelioration
Balb/c
mice,
with
cumulative
PASI
score
reduction
83.80%
57.14%
after
end
treatment.
In
addition,
insignificant
changes
histology
skin,
spleen,
liver
further
confirm
safety
developed
TAC-THQ-NLCs-gel.
Based
on
these
observations,
it
can
be
inferred
holds
promise
combined
treatment
approach
managing
topically.
Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown
Published: June 3, 2024
Language: Английский